SCHEMBL19087042

SCHEMBL19087042

Cc1cnn(Cc2cccc(Cl)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
KLKB1 P03952 3/20 0.47
KDM4E B2RXH2 1/20 0.47
SCD5 Q86SK9 1/20 0.47
ALK Q9UM73 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
ITK Q08881 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA2B P29275 1/20 0.45
ADORA1 P30542 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
TP53 P04637 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25583758 0.85 ALDH1A1 (0.54) L3MBTL1POLBTDP1KLKB1KMT2A
SCHEMBL130830 0.83 L3MBTL1 (0.62) L3MBTL1POLBTDP1KLKB1SCD5
SCHEMBL19117154 0.83 POLB (0.50) L3MBTL1POLBTDP1KLKB1KDM4E
SCHEMBL19077887 0.82 KDM4E (0.51) L3MBTL1POLBTDP1KLKB1KDM4E
SCHEMBL13813853 0.82 KCNH2 (0.53) KLKB1KDM4EKMT2ASMN1; SMN2MAPT
SCHEMBL1703637 0.81 KMT2A (0.63) L3MBTL1POLBTDP1KLKB1KDM4E
SCHEMBL16096120 0.81 L3MBTL1 (0.55) L3MBTL1POLBTDP1KLKB1KDM4E
SCHEMBL29442842 0.81 KMT2A (0.63) L3MBTL1POLBTDP1KLKB1KDM4E
SCHEMBL29281237 0.81 SCD (0.52) L3MBTL1KLKB1SCD5ALKADORA2A
SCHEMBL22479698 0.81 ITK (0.54) L3MBTL1POLBTDP1KLKB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023096928-A1 HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-06-01 WO disclosed
EP-3792256-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS Incyte Corporation (US) 2021-03-17 EP disclosed
EP-3400221-B1 PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2020-08-26 EP disclosed
WO-2017120194-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2017-07-13 WO disclosed
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190689-A1 PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS PIK3CG, PIK3CD, PIK3CB L3MBTL1 4436/4885POLB 630/4885TDP1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.